Live Coverage of OC Ophthalmology Technology Summit


In this week’s EyewireTV, the FDA allows Aerie Pharmaceuticals to change the primary endpoint range of its second phase 3 registration trial of glaucoma candidate Rhopressa; and Lensar receives CE Mark approval in Europe for its Streamline application upgrades. In the feature, some of the industry’s top business leaders at the Orange County Ophthalmology Technology Summit in Costa Mesa, California, share their thoughts on what they believe are the best investment opportunities in ophthalmology